In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heart Assist Companies Position for Longevity

Executive Summary

Recently, all three major players in the ventricular assist device market have consolidated. In May of this year, Baxter International merged its Novacor VAD business into World Heart. Not long after, Thoratec Laboratories acquired the ThermoCardiosystems division of Thermo Electron. Each deal had a different primary motive, but the companies all share a common goal of positioning their businesses for a long and expensive development process.

You may also be interested in...



Is there an Engineer in the House?

The recent clinical successes of artificial hearts and VADs knock over the first barrier to adoption of a new, life-saving therapy. But other hurdles remain, including providing the infrastructure to service large numbers of patients going about with extremely complicated, often quirky high-tech implantable devices on which their lives depend. The University of Pittsburgh is marshalling its bioengineering resources into a commercial entity, start-up Vital Engineering, which will be able to provide post-implant services on a wider, even global scale.

Thoratec's Bleeding Edge

The striking results of the REMATCH trial, demonstrating the efficacy of Thoratec's ventricular assist device to extend the life of terminal heart failure patients, is heartening clinicians and patients and opening up new markets for ventricular assist device manufacturers. Thoratec still faces FDA and reimbursement hurdles before its devices become long-term therapies in large volumes of patients. Meanwhile, the competition hopes to profit from the precedent-breaking REMATCH results, and overtake Thoratec's lead with claims of technological superiority in the long-term heart assist market.

AorTech's Staying Power

With its flagship product, a polyurethane-based heart valve, not yet in human trials, AorTech is in-licensing revenue-producing products, both in its core area of heart valves and in non-core critical care as well. The company hopes the strategy will give it the wherewithal to withstand a difficult financing environment and the doldrums of development.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

CO218085

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel